Data from Pharmawand - Curated by EPG Health - Date added 13 February 2018

Icon Bioscience announced that the FDA has approved IBI’s New Drug Application (NDA) for Dexycu (dexamethasone intraocular suspension), a dropless, long-acting therapeutic for treating inflammation associated with cataract surgery. Dexycu offers new treatment of inflammation in post cataract surgery because it is applied as a single injection administered at the conclusion of surgery. It employs IBI’s Verisome technology to dispense a biodegradable extended-release formulation of dexamethasone into the posterior chamber of the eye.

Approval follows positive data from its pivotal Phase III clinical trial for Dexycu in Cataract Surgery. The results of the trial showed that Dexycu is highly effective in treating inflammation post cataract surgery. In this trial, Dexycu showed unprecedented efficacy in reducing inflammation associated with cataract surgery, with a safety profile similar to that of placebo. It could prove to be an important new therapy as an alternative to frequent corticosteroid drop instillation in post cataract surgical care.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Type 2 Diabetes

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more.

Load more

Related Content